Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Reiteration

Reiteration

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $25 Price Target

By Benzinga Newsdesk
February 17, 7:16 AM
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.

VALN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Needham Reiterates Buy on Sage Therapeutics, Maintains $70 Price Target

By Benzinga Newsdesk
February 17, 7:14 AM
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Buy and maintains $70 price target.

SAGE

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Telsey Advisory Group Reiterates Outperform on Bath & Body Works, Maintains $52 Price Target

By Benzinga Newsdesk
February 17, 7:10 AM
Telsey Advisory Group analyst Dana Telsey reiterates Bath & Body Works (NYSE:BBWI) with a Outperform and maintains $52 price target.

BBWI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Telsey Advisory Group Reiterates Market Perform on Ross Stores, Maintains $120 Price Target

By Benzinga Newsdesk
February 17, 7:06 AM
Telsey Advisory Group analyst Dana Telsey reiterates Ross Stores (NASDAQ:ROST) with a Market Perform and maintains $120 price target.

ROST

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Barrington Research Reiterates Outperform on Avantax, Raises Price Target to $35

By Benzinga Newsdesk
February 17, 6:40 AM
Barrington Research analyst Alexander Paris reiterates Avantax (NASDAQ:AVTA) with a Outperform and raises the price target from $30 to $35.

AVTA

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Jefferies Reiterates Buy on Star Bulk Carriers, Maintains $26 Price Target

By Benzinga Newsdesk
February 17, 6:02 AM
Jefferies analyst Omar Nokta reiterates Star Bulk Carriers (NASDAQ:SBLK) with a Buy and maintains $26 price target.

SBLK

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Stephens & Co. Reiterates Overweight on Chuy’s Holdings, Maintains $33 Price Target

By Benzinga Newsdesk
February 17, 5:58 AM
Stephens & Co. analyst Joshua Long reiterates Chuy's Holdings (NASDAQ:CHUY) with a Overweight and maintains $33 price target.

CHUY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Canaccord Genuity Reiterates Buy on Repay Hldgs, Maintains $20 Price Target

By Benzinga Newsdesk
February 17, 5:54 AM
Canaccord Genuity analyst Joseph Vafi reiterates Repay Hldgs (NASDAQ:RPAY) with a Buy and maintains $20 price target.

RPAY

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

By Benzinga Newsdesk
February 17, 5:48 AM
Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

INZY

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings Beats
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Reiteration
  • Trading Ideas

Analyst Views West Pharmaceutical’s Q4 Earnings Impressive Despite Headwinds

By Vandana Singh
February 16, 1:48 PM
West Pharmaceutical Services Inc (NYSE:WST) reported Q4 2022 net sales of $708.7 million, down 3%, and organic net sales growth…

WST

Posts pagination

Previous 1 … 289 290 291 … 399 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service